Q: How does Adequan® Canine (polysulfated glycosaminoglycan or PSGAG) work?
Adequan® Canine (polysulfated glycosaminoglycan) binds to both albumin and chi- and beta-globulins and the extent of the binding is suggested to be 30 to 40%. Therefore, the drug may be present in both bound and free form in the bloodstream. As a result of its relatively low molecular weight, the synovial membrane is not a significant barrier to distribution of PSGAG from the bloodstream to the synovial fluid. Distribution from the synovial fluid to the cartilage takes place by diffusion. In the articular cartilage, the drug is deposited into the cartilage matrix.

 

Q: How is Adequan® Canine different from other canine arthritis treatments?
Adequan® Canine is a member of a unique class of drugs called disease-modifying osteoarthritis drugs (DMOADs) and contains a mixture of polysulfated GAGs (glycosaminoglycans) that can help it bind with connective tissue. Adequan® Canine delivers high levels of GAGs to synovial joints by avoiding the digestive enzymes of the GI tract. Its relatively low molecular weight (3,000 to 15,000 daltons) allows PSGAG to move from the bloodstream through the synovial membrane and into the synovial fluid. This injectable binds to components of cartilage matrix to help shield against further degradation, as well as inhibits catabolic enzymes. In addition, Adequan® Canine stimulates chondrocytes and synoviocytes to synthesize collagen, proteoglycans and Hyaluronic Acid (HA). This injectable enhances anabolic activity, while diminishing discomfort.

 

Q: How safe is Adequan® Canine?
At the recommended dose, Adequan® Canine has been well tolerated and its safety has been consistently demonstrated. No toxic effects have been observed in studies with recommended doses. Adverse reactions were rare, mild and transient. Safety studies of PSGAG in breeding, pregnant or lactating dogs have not been conducted. Nutraceuticals make similar claims; however, they have not been proven clinically because they are not reviewed and approved by the FDA for safety and efficacy.
 

Q: What is the recommended dosing and administration of Adequan® Canine?

 

The recommended dose of Adequan® Canine is 2mg/lb body weight (.02 mL/lb, or 1 mL per 50 lb), by intramuscular injection only, twice weekly for up to four weeks (maximum of 8 injections). Do not exceed the recommended dose or therapeutic regimen.  Do not mix Adequan® Canine with any other drugs or solvents.
 

Q: When will results be seen with Adequan® Canine?
To achieve the maximum benefits of Adequan® Canine, it is important that dogs receive the recommended dose of Adequan® Canine by intramuscular injection only, twice weekly for up to four weeks (maximum of eight injections).
 

Q: Are there any medical problems that dogs may have that would prohibit them from using Adequan® Canine?
Adequan® Canine should not be used in dogs showing hypersensitivity to PSGAG or in dogs with known or suspected bleeding disorders. It should be used with caution in dogs with renal or hepatic impairment. Possible side effects (pain at injection site, vomiting, diarrhea, depression and abnormal bleeding) were mild, transient and self-limiting. Safety studies of PSGAG in breeding, pregnant or lactating dogs have not been conducted.
 

Q: How can I obtain Adequan® Canine?
To order Adequan® Canine, please contact your Novartis Animal Health US, Inc. Sales Representative, Authorized Novartis Animal Health Distributor, Novartis Animal Health Customer Relations at 1-800-332-2761, or www.powervet.com.